Advertisement
Advertisement
TOVX
Theriva Biologics, Inc.
0.17
USDSponsored
0.00
-1.13%
Nov 06, 15:56 UTC -5
Closed
Pre-Market
0.17
0.00
+1.50%
Theriva Biologics, Inc. (TOVX) Earnings
TOVX Earnings Reports
Positive Surprise Ratio
TOVX beat 35 of 42 last estimates.
83%
Next Report
Tomorrow
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.06
Implied change from Q2 26 (Revenue/ EPS)
--
/-14.29%
Implied change from Q3 25 (Revenue/ EPS)
--
/-86.67%
Theriva Biologics, Inc. earnings per share and revenue
On Aug 11, 2026, TOVX reported earnings of -0.07 USD per share (EPS) for Q2 26, missing the estimate of -0.05 USD, resulting in a -37.25% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.43% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an decrease of -14.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
Ernexa Therapeutics Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$3.91
Actual
-$1.89
Surprise
+51.75%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
FAQ
What were Theriva Biologics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Theriva Biologics, Inc. reported EPS of -$0.07, missing estimates by -37.25%, and revenue of $0.00, 0% as expectations.
How did the market react to Theriva Biologics, Inc.'s Q2 2026 earnings?
The stock price moved down -0.43%, changed from $0.23 before the earnings release to $0.23 the day after.
When is Theriva Biologics, Inc. expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Theriva Biologics, Inc.'s next earnings report?
Based on 4
analysts, Theriva Biologics, Inc. is expected to report EPS of -$0.06 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.